Purpose: To determine the risk of fractures associated with sodium-glucose co-transporter 2 inhibitors (SGLT2i) compared with dipeptidyl peptidase-4 inhibitors (DPP4i).
Methods: We conducted a retrospective cohort study using data from the Truven Health MarketScan (2009-2015) databases. Our cohort included patients newly initiating treatment with SGLT2i or DPP-4i between 1 April 2013 and 31 March 2015 that were matched 1:1 using high dimensional propensity scores. Patients were followed up in an as-treated approach starting from initiation of treatment until the earliest of any fracture, treatment discontinuation, disenrollment, or end of data (31 December 2015). Risk of fractures was determined at any time during the follow-up, early in therapy (1-14 days of the follow-up), and later in therapy (15 days and beyond). Cox proportional hazards models were used to determine hazard ratios and robust 95% confidence intervals (95% CI).
Results: After matching, our cohort included 30 549 patients in each treatment group. Over a median follow-up of 219 days, there were 745 fractures overall. The most common site for fractures was the foot (32.7%). The effect estimates for fracture risk occurring at any time during follow-up, early in therapy, and later in therapy were HR 1.11 [95% CI 0.96-1.28], HR 1.82 [95% CI 0.99-3.32], and HR 1.07 [95% CI 0.92-1.24], respectively.
Conclusion: There is a possible increase in risk for fractures early in therapy with SGLT2i. Beyond this initial period, SGLT2is had no apparent effect on the incidence of fractures.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pds.4900 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Food Insecurity Is Common in the Orthopaedic Trauma Population.
J Am Acad Orthop Surg
January 2025
From the Department of Orthopedics and Rehabilitation, University of Iowa Hospitals and Clinics, Iowa City, IA (Willey, Miller, Temperly, Martin, Leary, Marsh, and Glass), Slocum Research and Education Foundation, Eugene, OR (Owen, Fitzpatrick, and Kirkpatrick), the Department of Health Policy and Management, Johns Hopkins Bloomberg school of Public Health, Baltimore, MD (Reider), and the Department of Orthopedic Surgery, Vanderbilt University Medical Center, Nashville, TN (Trochez, Wrenn, and Ponce).
Introduction: Food insecurity is the condition of limited access to healthy and safe food. Malnutrition resulting from food insecurity is a concern particularly in the surgical population due to the association with impaired healing. This aim of this study was to report the incidence and risk factors for food insecurity in the orthopaedic trauma population.
View Article and Find Full Text PDFDenosumab withdrawal increases vertebral fracture and mortality risk compared with zoledronate.
Eur J Endocrinol
January 2025
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Objective: Rebound vertebral fractures (VFs) after Denosumab (Dmab) withdrawal have been documented, highlighting the need for further research into this phenomenon and the importance of a well-planned strategy for discontinuing Dmab.
Methods: From the TriNetX US network, we enrolled osteoporosis patients aged 50 years or older who had withdrawn from at least two doses of Dmab and compared them with a matched cohort who had received at least one dose of zoledronate (ZOL) before discontinuation. We analyzed hazard ratios (HR) with 95% confidence intervals (CI) and conducted Kaplan-Meier analyses, along with subgroup analyses, drug discontinuation modification, and sensitivity analyses.
Sacral Alar-Iliac (SAI) screw diameter is not associated with pelvic fixation failure for neuromuscular scoliosis patients.
Spine Deform
January 2025
Jackie and Gene Autry Children's Orthopedic Center, Children's Hospital Los Angeles, 4650 Sunset Blvd, MS69, Los Angeles, CA, 90027, USA.
Purpose: Determine if Sacral Alar-Iliac (SAI) screw diameter is associated with pelvic fixation failure in pediatric patients with neuromuscular scoliosis (NMS) treated with posterior spinal fusion (PSF).
Methods: NMS patients from a single institution who underwent PSF with bilateral SAI screw fixation from 2010 to 2021 were retrospectively reviewed. Clinical parameters, SAI screw sizes, and radiographic outcomes were analyzed.
Risk Factors for 30-Day Readmission and Reoperation Following Clavicle Open Reduction Internal Fixation.
Cureus
December 2024
Orthopaedic Surgery, Stony Brook University Hospital, Stony Brook, USA.
Introduction Clavicle open reduction internal fixation (ORIF) is an effective treatment for the surgical management of clavicle fractures. However, the literature surrounding the risk factors for readmission and reoperation following clavicle ORIF remains understudied. The purpose of this study is to investigate the specific risk factors for 30-day readmission and reoperation following clavicle ORIF.
View Article and Find Full Text PDFMusculoskeletal adverse events associated with CDK4/6 inhibitors: a real-world study using FDA Adverse Event Reporting System (FAERS) database.
BMC Pharmacol Toxicol
January 2025
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Objective: Cyclin-dependent kinase (CDK)-4/6 inhibitors have significantly improved outcomes in several cancers but can also induce various organ system toxicities, including musculoskeletal disorders. This study aimed to comprehensively characterize the musculoskeletal adverse events (MSAEs) associated with CDK4/6 inhibitors based on real-world data.
Methods: Reports of MSAEs linked to CDK4/6 inhibitors from the first quarter (Q1) of 2015 and 2023 Q4 were extracted from the FAERS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!